Search Results - Gutzmer, R.

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial by Livingstone, Elisabeth (Author) , Gogas, H. J. (Author) , Kandolf, L. (Author) , Meier, F. (Author) , Eigentler, T. K. (Author) , Ziemer, M. (Author) , Terheyden, P. (Author) , Gesierich, A. (Author) , Herbst, R. A. (Author) , Kähler, K. C. (Author) , Ziogas, D. C. (Author) , Mijušković, Ž. (Author) , Garzarolli, M. (Author) , Garbe, C. (Author) , Roesch, A. (Author) , Ugurel, S. (Author) , Gutzmer, R. (Author) , Gaudy-Marqueste, C. (Author) , Kiecker, F. (Author) , Utikal, Jochen (Author) , Hartmann, M. (Author) , Miethe, S. (Author) , Eckhardt, S. (Author) , Zimmer, L. (Author) , Schadendorf, Dirk (Author) ,


    Get full text
    Article (Journal) Online Resource
  2. 2

    Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positiv... by Livingstone, Elisabeth (Author) , Gogas, H. (Author) , Kandolf-Sekulovic, L. (Author) , Meier, F. (Author) , Eigentler, T. K. (Author) , Ziemer, M. (Author) , Terheyden, P. A. M. (Author) , Gesierich, A. H. (Author) , Herbst, R. A. (Author) , Kähler, K. C. (Author) , Ziogas, D. C. (Author) , Mijuskovic, Z. (Author) , Garzarolli, M. (Author) , Garbe, C. (Author) , Roesch, A. (Author) , Ugurel, S. (Author) , Gutzmer, R. (Author) , Grob, J. J. (Author) , Kiecker, F. (Author) , Utikal, Jochen (Author) , Windemuth-Kieselbach, C. (Author) , Eckhardt, S. (Author) , Zimmer, L. (Author) , Schadendorf, Dirk (Author) ,


    Get full text
    Article (Journal) Online Resource
  3. 3

    Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT) by Saiag, Philippe (Author) , Gutzmer, R. (Author) , Ascierto, P. A. (Author) , Maio, M. (Author) , Grob, J. -J. (Author) , Murawa, P. (Author) , Dreno, B. (Author) , Ross, M. (Author) , Weber, J. (Author) , Hauschild, A. (Author) , Rutkowski, P. (Author) , Testori, A. (Author) , Levchenko, E. (Author) , Enk, Alexander (Author) , Misery, L. (Author) , Vanden Abeele, C. (Author) , Vojtek, I. (Author) , Peeters, O. (Author) , Brichard, V. G. (Author) , Therasse, P. (Author) ,


    Get full text
    Article (Journal) Online Resource
  4. 4

    Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial by Egberts, Friederike (Author) , Gutzmer, R. (Author) , Ugurel, S. (Author) , Becker, J. C. (Author) , Trefzer, U. (Author) , Degen, A. (Author) , Schenck, F. (Author) , Frey, L. (Author) , Wilhelm, T. (Author) , Hassel, Jessica C. (Author) , Schadendorf, D. (Author) , Livingstone, E. (Author) , Mauch, C. (Author) , Garbe, C. (Author) , Berking, C. (Author) , Rass, K. (Author) , Mohr, P. (Author) , Kaehler, K. C. (Author) , Weichenthal, M. (Author) , Hauschild, A. (Author) ,


    Get full text
    Article (Journal) Online Resource